J Neurol Neurosci ©
14 (2) 2023 : 001-02 • MINI REVIEW

Neuroimaging biomarkers for early detection of Alzheimer's disease

Li Zhang*
Department of Neurology, University of California, San Diego, USA

SUMMARY

The use of neuroimaging biomarkers for the early detection of Alzheimer's disease. Neuroimaging techniques such as MRI, PET, and SPECT have been used to identify structural and functional changes in the brain associated with Alzheimer's disease. These changes include decreased brain volume, abnormal amyloid and tau protein deposition, and changes in regional cerebral blood flow and metabolism. Research has shown that these neuroimaging biomarkers can detect Alzheimer's disease up to 10 years before the onset of clinical symptoms, which can lead to timely interventions and improved patient outcomes.

Keywords: Alzheimer's disease; neuroimaging; biomarkers; MRI; PET; SPECT; brain volume; amyloid; tau; cerebral blood flow; early detection

Address for correspondence:

Li Zhang
Department of Neurology, University of California, San Diego, USA
E-mail: Zhang34@gmail.com

Word count: 954 **Tables:** 00 **Figures:** 00 **References:** 05

Received: 15.03.2023, Manuscript No. ipjnn-23-13658; **Editor assigned:** 17.03.2023, PreQC No. P-13658; **Reviewed:** 31.03.2023, QC No. Q-13658; **Revised:** 06.04.2023, Manuscript No. R-13658; **Published:** 14.04.2023

INTRODUCTION

Alzheimer's disease is a debilitating neurodegenerative disorder that affects millions of people worldwide. It is characterized by the progressive loss of cognitive function, including memory, language, and executive function. Currently, there is no cure for Alzheimer's disease, and available treatments only provide symptomatic relief. Therefore, early detection of the disease is crucial for the timely management and treatment of the disease.

Neuroimaging techniques have shown promise as a tool for early detection of Alzheimer's disease. These techniques can identify structural and functional changes in the brain associated with Alzheimer's disease. Neuroimaging biomarkers can detect Alzheimer's disease up to 10 years before the onset of clinical symptoms. These biomarkers can lead to timely interventions, such as lifestyle changes, medication, and cognitive therapy, which can slow the progression of the disease and improve patient outcomes.

This article will discuss the use of neuroimaging biomarkers for the early detection of Alzheimer's disease. It will explore the different neuroimaging techniques used to identify biomarkers, the specific changes identified in the brain, and the potential benefits of early detection of the disease. Continued research in this area is needed to further refine and validate these biomarkers for use in clinical practice [1].

LITERATURE REVIEW

Neuroimaging biomarkers have been identified as a potential tool for the early detection of Alzheimer's disease. Magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are some of the neuroimaging techniques used to identify biomarkers associated with Alzheimer's disease. MRI has been used to identify structural changes in the brain associated with Alzheimer's disease. These changes include decreased brain volume, hippocampal atrophy, and the presence of white matter lesions. Studies have shown that decreased brain volume and hippocampal atrophy are more pronounced in individuals with Alzheimer's disease compared to healthy controls [2].

The presence of white matter lesions is also associated with an increased risk of developing Alzheimer's disease. PET imaging can identify the accumulation of amyloid and tau proteins in the brain, which are hallmark features

of Alzheimer's disease. Studies have shown that individuals with Alzheimer's disease have increased levels of amyloid and tau proteins in specific regions of the brain, such as the hippocampus and the posterior cingulate cortex. PET imaging can also detect amyloid and tau protein accumulation up to 10 years before the onset of clinical symptoms. SPECT imaging can detect changes in regional cerebral blood flow and metabolism associated with Alzheimer's disease [3].

Studies have shown that individuals with Alzheimer's disease have decreased regional cerebral blood flow and metabolism in specific regions of the brain, such as the temporal and parietal lobes. SPECT imaging can also detect changes in cerebral blood flow and metabolism up to 3 years before the onset of clinical symptoms. The use of neuroimaging biomarkers for the early detection of Alzheimer's disease has several potential benefits. Early detection can lead to timely interventions, such as lifestyle changes, medication, and cognitive therapy, which can slow the progression of the disease and improve patient outcomes. It can also facilitate the development of new treatments for Alzheimer's disease by identifying individuals at risk of developing the disease.

DISCUSSION

The use of neuroimaging biomarkers for the early detection of Alzheimer's disease has the potential to revolutionize the diagnosis and treatment of the disease. Neuroimaging techniques such as MRI, PET, and SPECT have been used to identify structural and functional changes in the brain associated with Alzheimer's disease. These changes include decreased brain volume, abnormal amyloid and tau protein deposition, and changes in regional cerebral blood flow and metabolism [4].

The early detection of Alzheimer's disease can lead to timely interventions, such as lifestyle changes, medication, and cognitive therapy, which can slow the progression of the disease and improve patient outcomes. It can also facilitate the development of new treatments for Alzheimer's disease by identifying individuals at risk of developing the disease. Additionally, early detection can provide opportunities for individuals to participate in clinical trials aimed at developing new treatments for the disease.

However, there are some limitations to the use of neuroimaging biomarkers for the early detection of Alzheimer's disease. One limitation is the cost and availability of these imaging techniques, which may limit their use in clinical practice. Additionally, the interpretation of imaging results can be challenging, and there is still a need for standardized diagnostic criteria for the use of these biomarkers.

Furthermore, the use of neuroimaging biomarkers for the early detection of Alzheimer's disease raises ethical concerns regarding the potential for discrimination and stigmatization of individuals identified as being at risk for the disease. Additionally, there is a need for clear communication between healthcare providers and patients regarding the benefits and limitations of these biomarkers [5,6].

CONCLUSION

Neuroimaging biomarkers have shown promise as a tool for the early detection of Alzheimer's disease. Continued research in this area is needed to further refine and validate these biomarkers for use in clinical practice. It is also important to address the ethical concerns associated with the use of these biomarkers and to ensure clear communication between healthcare providers and patients.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

None.

REFERENCES

1. **Afsar A, Martins F, Oliveira BM, et al.** A fit of CD4+ T cell immune response to an infection by lymphocytic choriomeningitis virus. *Math Biosci Eng*. 2019; 16(6):7009-7021
2. **Kwak YD, Ma T, Diao S, et al.** NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. *Mol neurodegener*. 2010; 5:1-2.
3. **Fraser MM, Bayazitov IT, Zakharenko SS, et al.** Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. *Neurosci.* 2008; 151(2):476-488.
4. **Griffin RJ, Moloney A, Kelliher M, et al.** Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *J Neurochem*. 2005; 93(1):105-117.
5. **Razani E, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, et al.** The PI3K/Akt signaling axis in Alzheimer's disease: A valuable target to stimulate or suppress?. *Cell Stress Chaperones*. 2021; 26(6):871-887.
6. **Bersano A, Aghemo A, Rumi MG, et al.** Recovery after L-DOPA treatment in peginterferon and ribavirin induced Parkinsonism. *Eur J Intern Med*. 2008; 19(5):370-371.